Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Regan

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Veterinary and Comparative Oncology|April 14, 2015
Treatment time, ease of use and cost associated with use of Equashield™, PhaSeal<sup>®</sup> , or no closed system transfer device for administration of cancer chemotherapy to a dog modelK Kicenuik, N Northrup, A Dawson, et al.
BMC Bioinformatics|November 4, 2010
Predicting success of oligomerized pool engineering (OPEN) for zinc finger target site sequencesJeffry D Sander, Deepak Reyon, Morgan L Maeder, et al.
Nature|January 7, 2005
Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expressionJeffrey D Rothstein, Sarjubhai Patel, Melissa R Regan, et al.
American Journal of Human Genetics|June 28, 2000
An optimized set of human telomere clones for studying telomere integrity and architectureS J Knight, C M Lese, K S Precht, et al.
Journal of Medical Genetics|March 10, 2001
Clinical studies on submicroscopic subtelomeric rearrangements: a checklistB B de Vries, S M White, S J Knight, et al.
European Journal of Cancer (Oxford, England : 1990)|February 3, 2024
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00S Rusakiewicz, S Tyekucheva, S Tissot-Renaud, et al.
Nature Cell Biology|January 14, 2022
Cysteine oxidation of copper transporter CTR1 drives VEGFR2 signalling and angiogenesisArchita Das, Dipankar Ash, Abdelrahman Y Fouda, et al.
Journal of Medical Genetics|June 14, 2008
Recurrent reciprocal deletions and duplications of 16p13.11: the deletion is a risk factor for MR/MCA while the duplication may be a rare benign variantF D Hannes, A J Sharp, H C Mefford, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Veterinary and Comparative Oncology|April 14, 2015
Treatment time, ease of use and cost associated with use of Equashield™, PhaSeal<sup>®</sup> , or no closed system transfer device for administration of cancer chemotherapy to a dog modelK Kicenuik, N Northrup, A Dawson, et al.
BMC Bioinformatics|November 4, 2010
Predicting success of oligomerized pool engineering (OPEN) for zinc finger target site sequencesJeffry D Sander, Deepak Reyon, Morgan L Maeder, et al.
Nature|January 7, 2005
Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expressionJeffrey D Rothstein, Sarjubhai Patel, Melissa R Regan, et al.
American Journal of Human Genetics|June 28, 2000
An optimized set of human telomere clones for studying telomere integrity and architectureS J Knight, C M Lese, K S Precht, et al.
Journal of Medical Genetics|March 10, 2001
Clinical studies on submicroscopic subtelomeric rearrangements: a checklistB B de Vries, S M White, S J Knight, et al.
European Journal of Cancer (Oxford, England : 1990)|February 3, 2024
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00S Rusakiewicz, S Tyekucheva, S Tissot-Renaud, et al.
Nature Cell Biology|January 14, 2022
Cysteine oxidation of copper transporter CTR1 drives VEGFR2 signalling and angiogenesisArchita Das, Dipankar Ash, Abdelrahman Y Fouda, et al.
Journal of Medical Genetics|June 14, 2008
Recurrent reciprocal deletions and duplications of 16p13.11: the deletion is a risk factor for MR/MCA while the duplication may be a rare benign variantF D Hannes, A J Sharp, H C Mefford, et al.
Pageof 8